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were associated with sustained virological response (SVR) in hepatitis C virus genotype 1
(HCV-1) infected patients treated with a standard 48-week regimen of peginterferon and riba-
virin combination. Whether IL28B SNP genotype would be the influential prognosticator for pa-
tients treated with response-guided therapy (RGT) is still not well understood.
Aims: To investigate the impact of IL28B rs809917 genotype on HCV-1 infected patients treated
with RGT.
Methods: A total of 128 consecutive treatment-naı¨ve HCV-1 infected patients between July
2006 and July 2011 were analyzed. For rapid virological response (RVR) patients, we allowed
an abbreviated 24-week regimen regardless of baseline viral loads; otherwise, a 48-week
regimen was implemented (for patients with early virological response). The IL28B
rs8099917 SNP genotypes were determined accordingly.
Results: A total of 117 patients (91.4%) were of rs8099917 TT genotype and 11 (8.6%) were of
GT/GG genotype. Eighty-two of the 128 (64.1%) patients achieved SVR, occurring in 54 of 67
RVR patients (80.6%) and 28 of 61 non-RVR patients (45.9%, p < 0.001). Compared to the
GT/GG genotype, patients with the TT genotype had significantly higher SVR rates (67.5%
vs. 27.3%; p Z 0.008) and low relapse rates (28.2% vs. 70.0%; p Z 0.006). The multivariate
analysis showed that RVR (odds ratio, 4.51; 95% confidence interval, 1.87e10.90; p Z 0.001)
and rs8099917 TT genotype (odds ratio, 6.91; 95% confidence interval, 1.53e31.17;
p Z 0.012) were independent factors associated with SVR.Hepato-Gastroenterology, Department of Internal Medicine, Tungs’ Taichung MetroHarbor Hospital,
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Hepatitis C virus (HCV) infection, a leading cause of end-stage
liver disease such as cirrhosis or hepatocellular carcinoma,
affects approximately 170 million individuals worldwide [1].
Prevention of new HCV infection and treatment of chronic
hepatitis C should be the primary goals to solve this clinical
exigency. Large pivotal randomized controlled clinical trials
have shown that a combination treatment with peginterferon
alpha-2a or alpha-2b and ribavirin leads to a sustained viro-
logical response (SVR) rate of 50% or higher [2e4].
The duration of treatment should be based on the HCV
genotype, and 48 weeks of treatment for patients with HCV
genotype 1 (HCV-1) infection was suggested as the standard
of care [1,4]. Rapid virological response (RVR), defined as
undetectable serum HCV at Week 4 of treatment, is
emerging as an important milestone in the treatment of
patients with chronic hepatitis C [1,5]. The integration of
RVR into treatment decision may identify the patients for
whom a truncated course of therapy is appropriate. By
contrast, confirmation of no RVR in spite of early virological
response (EVR; defined as negative or 2-log10 decline from
baseline of serum HCV RNA at Week 12) allows clinicians to
select the so-called slow responders among HCV genotype 1
infected patients, for whom 48e72 weeks of therapy could
be beneficial [5e12]. Such response-guided therapy (RGT),
a dynamic algorithm that involves individualized treatment
based on the on-treatment virological response, is widely
accepted in current prevailing guidelines [1].
Recent genome-wide associated studies have demon-
strated strong evidence that single-nucleotide poly-
morphisms (SNPs) of interleukin-28B (IL28B) were
significantly correlated with SVR when patients were
treated with a standard duration therapy [13e21]. Never-
theless, only a few studies have focused on whether IL28B
SNP phenotypes would be influential in achieving SVR in
patients treated with RGT [22]. The aim of this study was to
investigate the predictors of SVR in patients treated with
RGT in a real-life setting, in a single nontertiary regional
hospital in middle Taiwan. We particularly addressed the
impact of IL28B genotype on treatment responses.
Methods
Background: real-world setting in Taiwan and our
daily practice
Since October 2003, the Bureau of National Health Insur-
ance (BNHI) in Taiwan has instituted a hepatitis C trial
treatment program that reimburses the cost for a standard24-week combination therapy of peginterferon and riba-
virin regardless of genotypes. The concept of on-treatment
virological monitoring was not integrated into management
with standard therapy in our daily practice until July 2006.
After the introduction of the RGT concept, we urged our
patients to monitor their hepatitis C viral loads during
treatment. For HCV-1 infected patient who achieved an
RVR, we allowed an abbreviated 24-week regimen regard-
less of baseline viral loads; otherwise, patients received
the 48-week regimen at their own expense for extra med-
ications from the 25th week to the 48th week of treatment.
The BNHI finally agreed to a 48-week regimen for patients
without RVR (for details of on-treatment viral monitoring,
see below) after November 2009.Patients and therapeutic regimens
This study comprised 128 consecutive treatment-naı¨ve HCV-
1 infected patients between July 2006 and July 2011. Eligible
participants were patients with positive serum antibody to
HCV, who were older than 18 years, who had elevated
alanine aminotransferase, and who had HCV RNA detectable
in their sera by commercial nucleic acid tests. Patients were
excluded if they have mixed HCV genotypes infection, con-
current infections of hepatitis B virus (positive hepatitis B
surface antigen test), decompensated cirrhosis, neutropenia
(<1.5  109/L), thrombocytopenia (<80  109/L), anemia
(<12 g/dL), hepatocellular carcinoma, and uncontrolled
thyroid function. Informed consent was obtained from all
patients. The study was carried out in accordance with the
provisions of the 1975 Declaration of Helsinki and with the
approval of the Institutional Review Board of the hospital.
The starting dose of peginterferon alpha-2b was 1.5 mg/
kg/wk, and this was adjusted by 0.5-mg/kg decrements in
patients who developed adverse events attributable to
interferon. For patients receiving peginterferon alpha-2a,
the starting dose was fixed at 180 mg/wk, and this was
reduced by 45 mg/wk if needed. The starting dose of riba-
virin was adjusted by body weight and computed as follows:
<75 kg, 1000 mg/d; and 75 kg, 1200 mg/d. In general, we
reduced the dose of ribavirin by 200-mg decrements in
patients whose hemoglobin declined to <10 g/dL or in
those patients who developed other adverse effects
attributable to this drug. Erythropoietin treatment was
permitted if the hemoglobin level was <10 g/dL.Laboratory methods
Serum HCV RNA levels were determined by a quantitative
polymerase chain reaction assay (Cobas TaqMan HCV Test
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detection limit, 15 IU/mL). In our analysis, patients with a
baseline HCV RNA level of >600,000 IU/mL were considered
as having a high viral load. Human genomic DNA was
extracted from peripheral blood mononuclear cells by
QIAamp DNA Blood Mini Kit (Qiagen Inc., Valencia, CA,
USA). For IL28B rs8099917 SNP genotype determination, the
TaqMan 50 nuclease SNP genotyping assays were used. The
samples were analyzed using the Applied Biosystems Ste-
pOne and StepOnePlus Real-Time PCR Systems (Applied
Biosystems Inc., Foster City, CA, USA). All assay reagents
including primers and probes were purchased from Applied
Biosystems Inc. The discrimination between wild-type and
mutant alleles was achieved based on labeling the probes
with two different dyes: VIC for wild-type and FAM for
mutant alleles. Because routine fibrosis assessments ob-
tained from liver biopsy are not required by BNHI, we used
the aspartate aminotransferase (AST)/platelet ratio index
(APRI) to represent the severity of liver fibrosis, which was
calculated using the following equation:
(AST level/upper limit of normal range)/platelet counts
(109/L)  100 [23].Table 1 Baseline clinical characteristics and virological
features of patients with different rs8099917 genotypes.
Characteristics rs8099917
Genotype TT
(n Z 117)
Genotype
GT/GG (n Z 11)
p
Age, y 57.5  10.3 57.0  8.9 0.898
Male sex 64 (54.7) 6 (54.5) 0.992
BMI 25.4  3.7 25.5  4.7 0.978
ALT, IU/L 118.1  84.3 150.7  90.2 0.224
GGT, IU/L 87.8  165.4 126.8  165.6 0.477
APRI 1.9  1.7 1.8  1.4 0.890
Creatinine, mg/dL 0.9  0.3 0.9  0.2 0.688
DM 19 (16.2) 0 (0) 0.148
Baseline HCV RNA
In log IU/mL 6.1  0.9 6.1  0.8 0.968
<600,000 IU/mL 37 (31.6) 5 (45.5) 0.350
Data are presented as mean  SD or n (%).
ALT Z alanine aminotransferase; APRI Z aspartate amino-
transferase (AST)/platelet ratio index; BMIZ body mass index;
DM Z diabetes mellitus; GGT Z gamma-glutamyl trans-
peptidase; SD Z standard deviation.Assessment of adherence and efficacy
Patients who received 80% of both their total interferon
and ribavirin doses for 80% of the expected duration of
therapy were considered to be 80/80/80 adherent. The
treatment responses were determined using the intention-
to-treat (ITT) analysis, and we included any patient who
had taken at least one dose of medications in this study.
RVR was defined as undetectable serum HCV at Week 4 of
treatment. Complete (cEVR) and partial early virological
response (pEVR) were defined as negative or 2-log10 decline
from baseline of serum HCV RNA at Week 12. A delayed
virological response was defined as undetectable HCV RNA
at Week 24 in patients with pEVR. “Nonresponse” was
defined as a drop in HCV RNA level of <2 log10 from baseline
at Week 12. Lastly, the end-of-treatment virological
response (EOTVR) and SVR were defined as undetectable
HCV RNA at the end of treatment (EOT) and Week 24 after
EOT.
Statistical analysis
The descriptive statistics used were mean  standard de-
viation for continuous variables and proportion for cate-
gorical variables. The analysis was conducted using two-
sample t test, Pearson’s Chi-square test, and Fisher’s exact
test when appropriate. All statistical testing was two-tailed
at the 5% level. Logistic regression models were used to
evaluate possible predictors of treatment responses, and
results were reported as odds ratio (OR) and their 95%
confidence intervals (CIs). Covariates with a two-sided
p < 0.1 at univariate analysis were included in a multivar-
iate model, to determine the independent determinants.
For all tests, p < 0.05 was considered statistically signifi-
cant. The analysis software used was SPSS, version 17.0
(SPSS Inc., Chicago, IL, USA).Results
Patient profiles, stratified by IL28B rs8099917
genotypes
The IL28B rs8099917 genotypic analysis showed that 117
patients (91.4%) carried the TT genotype and the remaining
11 patients (8.6%) carried the GT/GG genotype. The basic
demographic, virological, and clinical features were similar
between the patients carrying the rs8099917 TT and GT/GG
genotypes (Table 1).
Virological responses
Of the 128 patients, five had premature discontinuation of
treatment. Thus, the discontinuation rate for this series
was 3.9%. An outline of the flow diagram used in this study
is shown in Fig. 1. Eighty-two of the 128 (64.1%) patients
achieved SVR, occurring in 54 of 67 RVR patients (80.6%)
and 28 of 61 non-RVR patients (45.9%, p < 0.001). For pa-
tients without RVR, 49 individuals achieved the goal of
cEVR, and nine attained delayed virological response; the
remaining three patients were determined to be nonre-
sponsive, and the treatment was terminated at Week 16.
The RVR, cEVR, and EOTVR rates were not different
between patients with IL28B rs8099917 TT and GT/GG ge-
notypes (Fig. 2). However, compared to the G carrying
allele (GT/GG), those with the homozygous TT genotype
had a significantly higher SVR rates (67.5% vs. 27.3%;
p Z 0.008) and low relapse rates (28.2% vs. 70.0%;
p Z 0.006; Fig. 2).
Predictors of RVR
As shown in Table 2, the univariate analysis demonstrated
that male sex, lower body mass index, and lower baseline
Figure 1 Flow diagram illustrating the treatment outcome. cEVR Z complete virological response; DVR Z delayed virological
response; EOTVR Z end-of-treatment virological response; NR Z nonresponse; pEVR Z partial virological response; RVR Z rapid
virological response; SVR Z sustained virological response.
28 T.-M. Chen et al.HCV RNA level <600,000 IU/mL were significantly associ-
ated with higher RVR rates (Table 2). Further multivariate
analysis revealed that both male sex (OR 5.25; 95% CI,
2.11e13.07; p < 0.001) and baseline HCV viral loads
<600,000 IU/mL (OR 7.75; 95% CI, 2.76e21.74; p < 0.001)
were predictors of an RVR. Noticeably, the IL28B rs8099917
genotype did not have any impact on the chance of RVR in
this study.Figure 2 Treatment response rates with different IL28B rs8099
indicate the patient numbers. The definition of cEVR was anyo
achievement of RVR. cEVR Z complete virological response; EOTV
logical response; SVR Z sustained virological response.Predictors of SVR
As shown in Table 3, patients with IL28B rs8099917 TT ge-
notype, HCV RNA level <600,000 IU/mL at baseline, and the
achievement of an RVR were factors predictive of SVR in
the univariate analysis. We then conducted the multivar-
iate analyses either by baseline factors only (Model 1, see
Table 3) or by incorporating the achievement of RVR into to917 genotypes. The Arabic numerals at the base of the bar
ne who cleared serum HCV at Week 12, regardless of the
R Z end-of-treatment virological response; RVR Z rapid viro-
Table 2 Univariate and multivariate analyses of baseline factors predictive of rapid virological response (RVR), all HCV-1
patients (n Z 128).
Univariate analysis Multivariate analysisa
RVR (n Z 67) Non-RVR (n Z 61) p OR 95% CI p
Male sex 47 (70.1) 23 (37.7) <0.001 5.25 2.11 13.07 <0.001
BMI <25 38 (56.7) 24 (39.) 0.050 1.06 0.45 2.51 0.895
ALT <80 IU/L 21 (31.3) 23 (37.3) 0.449
GGT <58 IU/L 37 (61.7) 26 (46.4) 0.100 2.18 0.92 5.16 0.077
Baseline HCV RNA level, <600,000 IU/mL 34 (50.7) 8 (13.1) <0.001 7.75 2.76 21.74 <0.001
Age <55 y 26 (38.8) 22 (36.1) 0.749
IL28B rs8099917 genotype TT (vs. GT/GG) 62 (92.5) 55 (90.5) 0.632
APRI, mean  SD 1.8  1.7 2.0  1.7 0.533
Data are presented as n (%) unless otherwise indicated.
ALT Z alanine aminotransferase; APRI Z aspartate aminotransferase (AST)/platelet ratio index; BMI Z body mass index;
CI Z confidence interval; GGT Z gamma-glutamyl transpeptidase; OR Z odds ratio; RVR Z rapid virological response; SD Z standard
deviation.
a Only covariates with p < 0.1 at univariate analysis were included in a multivariate model to determine independent determinants.
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result showed that baseline viral load <600,000 IU/mL (OR
2.77; 95% CI, 1.14e6.75; p Z 0.025) and the carriage of
IL28B rs8099917 TT genotype (OR 7.06; 95% CI, 1.66e30.10;
p Z 0.008) were independent factors associated with SVR.
In Model 2, only the attainment of an RVR (OR 4.51; 95% CI,
1.87e10.90; p Z 0.001) and the carriage of rs8099917 TT
genotype (OR 6.91; 95% CI, 1.53e31.17; p Z 0.012) were
independent factors associated with SVR, but not low viral
load (Table 3).
SVR rates stratified by IL28B SNP genotypes and
RVR achievements
Because both IL28B genotype and RVR were determinant
factors for SVR in the entire population, a group analysis ofTable 3 Univariate and multivariate analyses of baseline (and o
virological response (SVR), all HCV-1 patients (n Z 128).
Univariate analysis
SVR (n Z 82) Non-SVR (n Z 46) p
Male sex 49 (59.8) 21 (45.7)
BMI <25 41 (50.0) 21 (45.7)
ALT <80 IU/L 26 (31.7) 18 (39.1)
GGT <58 IU/L 39 (51.3) 24 (60.0)
Baseline HCV RNA level,
<600,000 IU/mL
32 (39.0) 10 (21.7)
Age <55 y 33 (40.2) 15 (32.6)
Adherence (80/80/80 rule) 67 (81.7) 32 (69.6)
With RVR 54 (65.9) 13 (28.3) <
IL28B rs8099917 genotype
TT (vs. GT/GG)
79 (96.3) 38 (82.6)
APRI, mean  SD 1.8  1.7 2.0  1.7
Data are presented as n (%) unless otherwise indicated.
ALT Z alanine aminotransferase; APRI Z aspartate aminotrans
CIZ confidence interval; GGTZ gamma-glutamyl transpeptidase; OR
virological response; SD Z standard deviation.
a Only covariates with p < 0.1 at univariate analysis were includedthe influence of IL28B SNP on SVR by stratifying the
achievement of RVR was performed. As plotted in Fig. 3,
the SVR rate was 83.9% in patients with RVR and favorable
IL28B rs8099917 TT genotype, which was significantly
higher than that in patients with the unfavorable IL28B
(GT/GG)/with RVR (40.0%, p Z 0.035), favorable IL28B
(TT)/without RVR (49.1%, p < 0.001), or unfavorable IL28B
(GT/GG)/without RVR (16.7%, p Z 0.005). Other compari-
sons for each pair of groups did not reach statistical
significance.
Predictors of SVR: subgroup analysis for either RVR
or non-RVR patients
In a subsequent analysis, we analyzed the predictors asso-
ciated with SVR limited to those who achieved an RVR: then-treatment factor in Model 2) factors predictive of sustained
Multivariate analysis,
Model 1
Multivariate analysis,
Model 2a
OR 95% CI p OR 95% CI p
0.124
0.637
0.396
0.372
0.046 2.77 1.14 6.75 0.025 1.49 0.55 4.04 0.437
0.392
0.115
0.001 d d d d 4.51 1.87 10.90 0.001
0.008 7.06 1.66 30.10 0.008 6.91 1.53 31.17 0.012
0.706
ferase (AST)/platelet ratio index; BMI Z body mass index;
Z odds ratio; RVRZ rapid virological response; SVRZ sustained
in a multivariate model to determine independent determinants.
Figure 3 SVR rates stratified by IL28B rs8099917 genotype and RVR. The Arabic numerals at the base of the bar indicate the
patient numbers. RVR Z rapid virological response; SVR Z sustained virological response.
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type predicted SVR (OR 7.80; 95% CI, 1.15e52.83;
p Z 0.035). Next, predictive factors associated with SVR
were investigated for those who did not achieve an RVR:
the multivariate analysis showed that only the achievement
of cEVR was determined to be the predictor of SVR (OR
5.65; 95% CI, 1.12e28.52; p Z 0.036).Discussion
The results of this study extended what is already known
about IL28B polymorphisms in patients with chronic hepa-
titis C by providing an insight into the relationship between
IL28B rs8099917 genotype and virological response for HCV-
1 infected patients treated with RGT. In our study, the
combination of RVR and IL28B favorable genotype provided
the best predictors of SVR, whereas the IL28B unfavorable
genotype was a risk factor for relapse after treatment. For
non-RVR patients, the achievement of cEVR, regardless of
IL28B genotype, was the only prognosticator of SVR under
the current RGT.
Low baseline viral loads predicted the attainment of an
RVR in this study, which was not novel and was well
investigated in volumes of studies in the past [19]. The
impact of sex on treatment efficacy remains debatable.
After adjusting for other factors including baseline viral
loads, we found that male sex had a higher chance of RVR in
the current study. The finding was in line with recent re-
ports from Taiwan and Japan that male sex was one factor
associated with good virological responses [15,19].
In general, favorable IL28B genotypes enhance early
viral kinetics and SVR in HCV-1 patients [13,15,17e19,21];
unfavorable IL28B genotypes have been associated with
slower viral decline and poor treatment efficacy, and this
effect was particularly enhanced in patients who failed to
achieve an RVR at Week 4 [17e19,21]. We did not find an
association between IL28B rs8099917 genotypes and RVR
rate. The small sample size in the current study is onepossible explanation. Despite this, we clearly demonstrated
that patients who carried unfavorable IL28B genotypes had
higher relapse rates under the current RGT (Fig. 2).
Recently, Scherzer et al [22] also reported that relapse
rates were lower among patients with a favorable IL28B
genotype, and the extension of treatment duration was
warranted for those who carried unfavorable alleles.
Regarding the achievement of an SVR, Model 1 (only
baseline factors were included) showed that a lower
baseline viral load and IL28B genotype affected the SVR
rates. However, when RVR was taken into consideration in
Model 2, the attainment of an RVR and IL28B genotype were
predictors of SVR, but not baseline viral loads. Further-
more, for RVR patients (and all of them received an
abbreviated 24-week treatment), IL28B genotype was the
only predictor of SVR. When we analyzed the combination
effect of these two prognosticators (IL28B and RVR) on SVR,
as plotted in Fig. 3, the SVR rate was 83.9% in patients with
dual favorable factors, which yielded the highest treatment
success rate compared to those patients who only had
either one or no favorable factor. Previous studies have
demonstrated that abbreviated therapy will not signifi-
cantly compromise the likelihood of SVR among those who
had achieved an RVR. Herein, we learned that this was not
the case in the era of IL28B genotypic polymorphisms. Our
important finding emphasized that an abbreviated 24-week
therapy was suboptimal and should be avoided in RVR pa-
tients who had unfavorable IL28B genotype. We therefore
suggested that IL28B genotypes be tested for all patients
who had achieved an RVR. In line with our results, Liu et al
[21] concluded that we could adopt the favorable L28B
genotype plus RVR predicting rule to truncate treatment
duration when patients are concerned about adverse
events and increased medical costs.
Although the attainment of an RVR is the landmark of
treatment success, only half of HCV-1 infected patients
were able to achieve it in this study. More attention should
be paid to patients who failed to reach the early goal. For
non-RVR patients, we showed that only the achievement of
IL28B on HCV-1 infected patients treated with RGT 31cEVR and none of the baseline factors including IL28B ge-
notype was determined to be the predictor of SVR. Our
results prompted us to raise the important findings provided
by Liu et al [20] regarding treatment effects of slow re-
sponders. They found that, for HCV-1 infected patients
without RVR, the effects of IL28B genotype decreased when
the on-treatment viral response (at Week 8 and Week 12)
were taken into consideration; and IL28B polymorphisms
play only a minor role in identifying optimal treatment
duration in HCV-1 infected slow responders [20]. Although
we could not totally ignore the discriminatory power of the
IL28B genotypes in non-RVR patients [19], our results
highlighted that the achievement of cEVR was the most
important factor to ensure treatment success for patients
who failed to clear HCV during the first 4 weeks. Providing
and maintaining the optimal dose of treatment within 12
weeks of treatment was pivotal for the attainment of cEVR,
and every effort has to be made to achieve the second goal,
cEVR, if patients failed to achieve RVR.
Previously, we did find that treatment adherence was an
influential prognosticator among the treated cohort [24].
However, in this study, treatment adherence was not a
prognosticator after the analyses. The reason may be that
the discontinuation rate was low (3.9%) and the achieve-
ment rate of 80/80/80 adherent was already high (77.3%) in
this series. In this intention-to-treat analysis, we certainly
did not exclude patients who did not fulfill the 80/80/80
adherence rule, because the aim of this study was not an
exploratory analysis of the influence of IL28B genotype on
treatment responses. We believed that the study design we
built here could provide information on useful prognosti-
cators in our daily practice in a real-world setting. How-
ever, the major findings were not altered even if we
excluded the 29 noncompliant patients who failed to meet
the 80/80/80 adherent rule (data not shown).
The limitation of the current study is its retrospective
nature, and the case number in certain subgroups might be
too small. In addition, the completed histological data were
unavailable in the current study, and we used the APRI
score instead to represent the severity of liver disease
[18,19,23]. The current study did not find any association
between APRI score and treatment responses. Lastly, the
definition of an RVR achievement in this study (undetect-
able HCV RNA, <15 IU/mL) was more stringent than the
common one used in previous reports (HCV RNA <50 IU/
mL). However, as one important finding we emphasized
here was that an abbreviated 24-week therapy was sub-
optimal and should be avoided in RVR patients who had
unfavorable IL28B genotype, we believed that using the
stringent definition of RVR achievement was more relevant
to our conclusion.
In conclusion, the results of this analysis confirmed the
importance of IL28B genotype and on-treatment virological
response in HCV-1 patients undergoing RGT. The combina-
tion of RVR and IL28B favorable genotype provided the best
predictor of abbreviated 24-week treatment duration,
whereas the IL28B unfavorable genotype was a risk factor
of relapse after treatment. For HCV-1 infected patients
without RVR, the achievement of cEVR, regardless of the
IL28B genotype, was the only prognosticator of SVR under
the current RGT.Conflicts of interest
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